NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the first quarter were down 29 percent year over year but the firm still beat the consensus analyst estimate on the top and bottom lines.

The company said that for the three months ended March 31, revenues totaled $7.9 million, compared to $11.1 million in the year-ago quarter, and easily surpassing the average analyst estimate of $6.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.